Highest development stage: Phase 3 (Korean FDA)

Development status: Approved (Korean FDA)

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: For use against urinary (approved) and respiratory tract infections; inhibits DNA gyrase and topoisomerase IV enzymes

Additional information: Synthetic compound; a fourth generation fluoroquinolone